178 related articles for article (PubMed ID: 24722219)
21. Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999.
Cotten-Oldenburg NU; Carr P; DeBoer JM; Collison EK; Novotny G
J Acquir Immune Defic Syndr; 2001 Jun; 27(2):183-92. PubMed ID: 11404541
[TBL] [Abstract][Full Text] [Related]
22. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution?
Lurie P; Jones TS; Foley J
J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 18 Suppl 1():S45-51. PubMed ID: 9663623
[TBL] [Abstract][Full Text] [Related]
23. A qualitative study on pharmacy policies toward over-the-counter syringe sales in a rural epicenter of US drug-related epidemics.
Fadanelli M; Cooper HLF; Freeman PR; Ballard AM; Ibragimov U; Young AM
Harm Reduct J; 2022 Jan; 19(1):1. PubMed ID: 34996466
[TBL] [Abstract][Full Text] [Related]
24. Access to sterile syringes in Maine: pharmacy practice after the 1993 repeal of the syringe prescription law.
Case P; Beckett GA; Jones TS
J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 18 Suppl 1():S94-101. PubMed ID: 9663631
[TBL] [Abstract][Full Text] [Related]
25. Syringe laws and pharmacy regulations are structural constraints on HIV prevention in the US.
Taussig JA; Weinstein B; Burris S; Jones TS
AIDS; 2000 Jun; 14 Suppl 1():S47-51. PubMed ID: 10981474
[TBL] [Abstract][Full Text] [Related]
26. Negotiating access: social barriers to purchasing syringes at pharmacies in Tijuana, Mexico.
Davidson PJ; Lozada R; Rosen PC; Macias A; Gallardo M; Pollini RA
Int J Drug Policy; 2012 Jul; 23(4):286-94. PubMed ID: 22676968
[TBL] [Abstract][Full Text] [Related]
27. Injection drug users' perspectives on placing HIV prevention and other clinical services in pharmacy settings.
Lutnick A; Case P; Kral AH
J Urban Health; 2012 Apr; 89(2):354-64. PubMed ID: 22231488
[TBL] [Abstract][Full Text] [Related]
28. Pharmacy syringe sale practices during the first year of expanded syringe availability in New York City (2001-2002).
Finkelstein R; Tiger R; Greenwald R; Mukherjee R
J Am Pharm Assoc (Wash); 2002; 42(6 Suppl 2):S83-7. PubMed ID: 12489622
[TBL] [Abstract][Full Text] [Related]
29. More pharmacists in high-risk neighborhoods of New York City support selling syringes to injection drug users.
Coffin PO; Ahern J; Dorris S; Stevenson L; Fuller C; Vlahov D
J Am Pharm Assoc (Wash); 2002; 42(6 Suppl 2):S62-7. PubMed ID: 12489618
[TBL] [Abstract][Full Text] [Related]
30. Pharmacists' attitudes and practices about selling syringes to people who inject drugs in Tajikistan: Results of a syringe purchase audit and a survey.
Ibragimov U; Haardörfer R; Cooper HLF; Dunkle KL; Zule WA; Wong FY
Int J Drug Policy; 2019 Sep; 71():62-72. PubMed ID: 31226505
[TBL] [Abstract][Full Text] [Related]
31. Injection drug users report good access to pharmacy sale of syringes.
Reich W; Compton WM; Horton JC; Cottler LB; Cunningham-Williams RM; Booth R; Singer M; Leukefeld C; Fink J; Stopka TJ; Corsi KF; Tindall MS
J Am Pharm Assoc (Wash); 2002; 42(6 Suppl 2):S68-72. PubMed ID: 12489619
[TBL] [Abstract][Full Text] [Related]
32. Nonprescription syringe sales: a missed opportunity for HIV prevention in California.
Pollini RA; Rudolph AE; Case P
J Am Pharm Assoc (2003); 2015; 55(1):31-40. PubMed ID: 25575149
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of providing interventions for injection drug users in pharmacy settings: a case study among San Francisco pharmacists.
Rose VJ; Lutnick A; Kral AH
J Psychoactive Drugs; 2014; 46(3):226-32. PubMed ID: 25052881
[TBL] [Abstract][Full Text] [Related]
34. Should pharmacists have a role in harm reduction services for IDUs? A qualitative study in Tallinn, Estonia.
Vorobjov S; Uusküla A; Abel-Ollo K; Talu A; Jarlais DD
J Urban Health; 2009 Nov; 86(6):918-28. PubMed ID: 19921542
[TBL] [Abstract][Full Text] [Related]
35. Comparison of injection drug users accessing syringes from pharmacies, syringe exchange programs, and other syringe sources to inform targeted HIV prevention and intervention strategies.
Rudolph AE; Crawford ND; Ompad DC; Benjamin EO; Stern RJ; Fuller CM
J Am Pharm Assoc (2003); 2010 Mar-Apr 1; 50(2):140-7. PubMed ID: 20199954
[TBL] [Abstract][Full Text] [Related]
36. Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws.
Gleghorn AA; Gee G; Vlahov D
J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 18 Suppl 1():S89-93. PubMed ID: 9663630
[TBL] [Abstract][Full Text] [Related]
37. Explaining the relationship between race/ethnicity and pharmacy purchased syringes among injection drug users in New York City.
Fuller CM; Galea S; Blaney S; Ompad DC; Deren S; Des Jarlais D; Vlahov D
Ethn Dis; 2004; 14(4):589-96. PubMed ID: 15724781
[TBL] [Abstract][Full Text] [Related]
38. Over-the-counter but out of reach: a pharmacy-based survey of OTC syringe sales in Tijuana, Mexico.
Pollini RA; Gallardo M; Ruiz S; Case P; Zaller N; Lozada R
J Health Care Poor Underserved; 2014 May; 25(2):637-51. PubMed ID: 24858873
[TBL] [Abstract][Full Text] [Related]
39. Pharmacist attitudes and provision of harm reduction services in North Carolina: an exploratory study.
Parry RA; Zule WA; Hurt CB; Evon DM; Rhea SK; Carpenter DM
Harm Reduct J; 2021 Jul; 18(1):70. PubMed ID: 34238306
[TBL] [Abstract][Full Text] [Related]
40. Come back when you're infected: pharmacy access to sterile syringes in an Arizona Secret Shopper Study, 2023.
Russell DM; Meyerson BE; Mahoney AN; Garnett I; Ferrell C; Newgass K; Agley JD; Crosby RA; Bentele KG; Vadiei N; Frank D; Linde-Krieger LB
Harm Reduct J; 2024 Feb; 21(1):49. PubMed ID: 38388463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
